Alternate-Day Buprenorphine Administration. Phase VII - 8

Completed · Phase 2

Conditions studied: Opioid-Related Disorders

In brief

The purpose of this study is to determine if four times a subjects daily maintenance dose will hold for 96 hours without changes in agonist and antagonist effects under open dosing conditions.

Key facts

Study ID

NCT00000226

Run by

National Institute on Drug Abuse (NIDA)

People needed

0

Starts

1994-11-01

Last updated by the study team

2005-06-24

Who can join

Age: 21 and older, up to 48. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Treatment Research Center — Burlington, Vermont, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.